Boston, MA 06/03/2013 (wallstreetpr) – The share prices of Biodel Inc. (NASDAQ:BIOD) had surged by 10.40 percent to close at $4.67 per share for the end of last trading session on Friday. The specialty pharmaceutical company with focus on development and commercialization of innovative treatments for diabetics had recently shifted its 52 week high price level to $4.59 per share on the trading session of Friday. The 52 week low price level of Biodel Inc. (NASDAQ:BIOD) is at $2.93, which was hit when the company announced its financial results for the second quarter of fiscal 2013.
From then on, the share prices of Biodel Inc. (NASDAQ:BIOD) had been gradually increasing to close at $4.67 per share on Friday. The company is involved in the treatment and commercialization of innovative, safer, effective and convenient treatment therapies for diabetics patients and had recently developed and patented a drug delivery technology called Viadel. This technology is applicable to a range of peptides, proteins and other macromolecules.
Biodel Inc. (NASDAQ:BIOD) is now involved in development of Viadel for the delivery of insulin to patients with Type I and Type II diabetes. In the recently released financial results for the second quarter, 2013, the company had reported a net loss of $5.2 million or $0.37 per basic and diluted share compared to the net loss of $4.3 million or $0.45 per basic and diluted share for the same quarter of previous year. There had also been an increase in research and development expenses of Biodel Inc. (NASDAQ:BIOD) owing to the ongoing phase 2 clinical trials of BIOD-123.
